Vimarsana
Biggest News Aggregation in the World

Page 5 - Accelerate Commercialization News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accelerate Commercialization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accelerate Commercialization Today - Breaking & Trending Today

Perrigo's generics split is back on the docket, thanks to $1.55B Altaris offer - Vimarsana News

Perrigo's generics split is back on the docket, thanks to $1.55B Altaris offer

Perrigo is selling its prescription generics business to Altaris Capital Partners for $1.55 billion. The generics unit, which recently nabbed approval for a copycat version of Teva's ProAir HFA inhaler, will establish itself as a standalone company, investment firm Altaris said. The deal is expected to close by the end of the third quarter.

Fierce Pharma Asia—Daiichi Sankyo's new R&D head; Clover's $230M raise; Insilico's AI breakthrough - Vimarsana News

Fierce Pharma Asia—Daiichi Sankyo's new R&D head; Clover's $230M raise; Insilico's AI breakthrough

Daiichi Sankyo, Clover Biopharmaceuticals and Insilico Medicine made our news this week. (Google) Amid a big cancer push, Daiichi Sankyo lured Kite Pharma exec Ken Takeshita to lead its R&D work. China's Clover Biopharmaceuticals secured $230 million in an oversubscribed series C to help advance its COVID-19 vaccine program and expand manufacturing capabilities. In several firsts for artificial-intelligence-based drug discovery, Insilico Medicine discovered a novel target for idiopathic pulmonary fibrosis, designed a new molecule and validated it in preclinical models in 18 months. And more...